Redhill Biopharma Ltd (RDHL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has a cash flow conversion efficiency ratio of 0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.51 Million) by net assets ($-4.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RDHL company net worth for the company's overall valuation and market capitalisation.
Redhill Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Redhill Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Redhill Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Redhill Biopharma Ltd ranked by their cash flow conversion efficiency. Explore Redhill Biopharma Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sparta Capital Ltd
V:SAY
|
-0.429x |
|
MANTLE MINERALS
F:MXB0
|
N/A |
|
Nrgene Technologies Ltd
TA:NRGN
|
0.392x |
|
Mare Nostrum
PA:ALMAR
|
-0.054x |
|
Techgen Metals Ltd
AU:TG1
|
-0.102x |
|
Marston’s PLC
LSE:MARS
|
0.029x |
|
Social Housing REIT plc
LSE:SOHO
|
0.034x |
|
South HARZ Potash Ltd
AU:SHP
|
-0.877x |
Annual Cash Flow Conversion Efficiency for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Redhill Biopharma Ltd from 2010 to 2025. View Redhill Biopharma Ltd (RDHL) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.27 Million | $-9.65 Million | -2.261x | -213.03% |
| 2024-12-31 | $-4.68 Million | $-9.37 Million | 2.001x | +111.56% |
| 2023-12-31 | $2.07 Million | $-35.82 Million | -17.313x | -2971.10% |
| 2022-12-31 | $-48.40 Million | $-29.18 Million | 0.603x | +108.23% |
| 2021-12-31 | $8.88 Million | $-65.05 Million | -7.329x | -109.17% |
| 2020-12-31 | $13.86 Million | $-48.58 Million | -3.504x | -415.95% |
| 2019-12-31 | $60.00 Million | $-40.75 Million | -0.679x | -0.87% |
| 2018-12-31 | $51.19 Million | $-34.46 Million | -0.673x | +32.23% |
| 2017-12-31 | $45.06 Million | $-44.77 Million | -0.993x | -120.43% |
| 2016-12-31 | $62.70 Million | $-28.26 Million | -0.451x | -51.89% |
| 2015-12-31 | $60.08 Million | $-17.83 Million | -0.297x | +39.31% |
| 2014-12-31 | $25.01 Million | $-12.23 Million | -0.489x | +30.88% |
| 2013-12-31 | $11.93 Million | $-8.44 Million | -0.707x | -97.99% |
| 2012-12-31 | $19.02 Million | $-6.79 Million | -0.357x | -43.09% |
| 2011-12-31 | $18.79 Million | $-4.69 Million | -0.250x | -124.39% |
| 2010-12-31 | $-1.59 Million | $-1.63 Million | 1.024x | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more